|Title||Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.|
|Publication Type||Journal Article|
|Year of Publication||2022|
|Authors||Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E|
Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into the treatment landscape of TNBC have led to improved outcomes in a subset of patients both in the early stage and metastatic settings. However, a large portion of patients with TNBC remain resistant to immune checkpoint inhibitors and have limited treatment options beyond cytotoxic chemotherapy. The interplay between the anti-tumor immune response and tumor metabolism contributes to immunotherapy response in the preclinical setting, and likely in the clinical setting as well. Specifically, tumor glycolysis and lactate production influence the tumor immune microenvironment through creation of metabolic competition with infiltrating immune cells, which impacts response to immune checkpoint blockade. In this review, we will focus on how glucose metabolism within TNBC tumors influences the response to immune checkpoint blockade and potential ways of harnessing this information to improve clinical outcomes.
|Alternate Journal||Front Oncol|
|PubMed Central ID||PMC9872136|
|Grant List||P30 CA008748 / CA / NCI NIH HHS / United States|
Sandra Demaria, M.D.